
Cipla’s antiviral drug Cipremi joins Fabiflu, Covifor to treat Covid-19 infection
Pharma major Cipla Ltd has announced the launch of its generic version of antiviral drug Remdesivir for emergency use in treatment of Covid-19 patients. The new drug will be sold under the brand name Cipremi.
Cipla’s antiviral drug Cipremi is the latest to join Glenmark’s Fabiflu and Hetero’s Covifor to treat Covid-19 patients in the country.
Last week, the Union Health Ministry included the use of antiviral drug Remdesivir as part of “investigational therapy” in India only for restricted emergency-use in its updated Clinical Management Protocol for Covid-19 patients. Off-label application of immunomodulator tocilizumab and convalescent plasma therapy for treating coronavirus patients in moderate stage of criticality, were also approved by the ministry.
ALSO READ | Remdesivir, now part of Covid-19 therapy in Centre’s new health protocol document
Remdesivir, happens to be the only USFDA approved Emergency Use Authorisation (EUA) treatment for adults and children hospitalised with suspected or laboratory confirmed coronavirus infection.
At a time when nearly 200 countries across the globe are grappling with the Covid-19 pandemic, Gilead Sciences Inc extended a voluntary non-exclusive license to India-based Cipla to manufacture and market the generic version of Remdesivir called Cipremi.
The pharma firm has been granted regulatory approval by the Drug Controller General of India (DCGI) for restricted emergency use in the country as part of the accelerated approval process considering the urgent medical need with a surge in Covid-19 cases in India, which have crossed the 4,00,000-mark.
Prices of the drug in the Indian market are yet to be announced by Cipla.
“As part of a risk management plan, Cipla will provide training on the use of the drug, inform patients for consent documents, conduct post marketing surveillance as well as conduct a Phase-IV clinical trial on Indian patients,” the company said in a statement.
ALSO READ | Glenmark’s FabiFlu gets DCGI nod as Covid-19 drug, in stores next week
“Cipla appreciates the strong partnership with Gilead to bring Remdesivir to patients in India. We have been deeply invested in exploring all possible avenues to save millions of lives impacted by the Covid-19 pandemic, and this launch is a significant milestone in that direction,” MD and Global CEO Umang Vohra said.
So that coronavirus patients can get quick access to this treatment and in anticipation of high demand, Cipla will be commercializing Remdesivir through its own facilities and partnered sites, the company statement said.
The drug will be supplied through the government and open market channels to ensure equitable distribution, the statement read.
On the Bombay Stock Exchange (BSE), shares of Cipla climbed over 9% in Monday’s trade after the pharma major announced the launch of its generic version of Remdesivir.

Mamata Banerjee hails from 'demoness' culture, has faulty DNA: BJP MLA in UP

Farmers protest: AAP ups ante, quotes RTI document to slam Amarinder Singh

In a first, Ladakh tableau to be part of Republic Day parade

Bodo accord has brought peace to BTR, says Amit Shah in Kokrajhar, Assam
- Shah mentioned how the Bodo accord was crucial in ensuring a peaceful election to the Bodo Territorial Council (BTC) held last month. He lambasted the opposition Congress for failing to fulfil promises.

UP govt orders no diesel for tractors as farmers gear up for Jan 26 rally

Security tightened in Kashmir Valley ahead of Republic Day

Rahul Gandhi slams Centre for Tamil Nadu's 'economic downturn'

Ageing dams in India, US, other nations pose growing threat: UN report

Centre committed to empowering women: Harsh Vardhan

Farmers prep for Republic Day tractor rally; no clarity yet on police permission

ASHA worker's death sparks protests in Andhra; coworkers, kin suspect AEFI

'Playing important role in building self-reliant India': PM greets on UP Diwas

Digital voter cards: How to download? Who are eligible? All you need to know

Priyanka Gandhi slams Centre for blocking farmers from entering Delhi
